AZN

Summit Therapeutics is expanding its investigational drug ivonescimab beyond non-small cell lung cancer into colorectal and bladder cancer indications. The company has initiated phase III trials for metastatic colorectal cancer and phase II/III studies for advanced bladder cancer.

Strategic partnerships with AstraZeneca, GSK, and Arcus Biosciences are evaluating ivonescimab in combination with other cancer therapies, with AstraZeneca committing $2 billion in investment. An FDA decision on ivonescimab for EGFR-mutated NSCLC is expected by November 2026.

VanEck Biotech ETF (BBH) has reached a 52-week high, rising 41.1% from its low, driven by positive Phase 3 results for Amgen and AstraZeneca's Tezspire treatment for eosinophilic esophagitis. The fund shows a positive weighted alpha of 44.96, suggesting potential for continued gains in the near term.

Zacks highlights four breast cancer drug stocks for Breast Cancer Awareness Month. AstraZeneca and Roche are established large-cap pharma companies with strong commercial portfolios and pipeline opportunities.

Puma Biotechnology relies on Nerlynx sales with a mid-stage pipeline candidate. Olema Oncology is a clinical-stage company dependent on its lead candidate palazestrant's phase III trial results expected in Q1 2027.